New Breakthroughs in Cancer Immunotherapy | Your Morning

Cancer researchers are expressing a new wave of optimism as major advancements in immunotherapy take center stage. Recently, the UK National Institute for Health and Care Excellence approved pembrolizumab (Keytruda) for the treatment of advanced cervical cancer - a move that marks a significant milestone in the field. This approval is just one of many breakthroughs happening globally, including critical cancer research occurring right here in Canada. We are joined by Dr. Robert Vonderheide, President-elect of the American Association for Cancer Research (AACR) and Director of the Abramson Cancer Center at Penn Medicine, to discuss why 2026 is becoming a pivotal year for cancer immunotherapy breakthrough and what these new cancer treatment updates mean for the future of patient care and survival. #CancerResearch #Immunotherapy #CervicalCancer #AACR #HealthNews #CancerTreatment #MedicalBreakthrough #PennMedicine #Pembrolizumab #CancerHope #ScienceNews #CanadaHealth Subscribe to Your Morning for the latest: http://bit.ly/2hX11GF Connect with Your Morning: https://www.ctv.ca/shows/your-morning Follow Your Morning on TikTok: https://www.tiktok.com/@yourmorningctv Start YOUR MORNING with us. Hosts Anne-Marie Mediwake, Lindsey Deluce & Kelsey McEwen get you up to date on what Canadians will be talking about today, weekday mornings on CTV & CTV News Channel, 6am-9am ET (7am-10am AT, 730am-1030am NT)